AU2012357637B9 - Prevention and treatment of Mycobacterium infection - Google Patents

Prevention and treatment of Mycobacterium infection Download PDF

Info

Publication number
AU2012357637B9
AU2012357637B9 AU2012357637A AU2012357637A AU2012357637B9 AU 2012357637 B9 AU2012357637 B9 AU 2012357637B9 AU 2012357637 A AU2012357637 A AU 2012357637A AU 2012357637 A AU2012357637 A AU 2012357637A AU 2012357637 B9 AU2012357637 B9 AU 2012357637B9
Authority
AU
Australia
Prior art keywords
mycobacterium
tuberculosis
bcg
infection
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012357637A
Other languages
English (en)
Other versions
AU2012357637B2 (en
AU2012357637A1 (en
Inventor
Warwick John BRITTON
Rachel PINTO-NADANACHANDRAN
James Anthony TRICCAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centenary Institute of Cancer Medicine and Cell Biology
The University of Sydney
Original Assignee
Centenary Inst Of Cancer Medicine And Cell Biology
Centenary Institute of Cancer Medicine and Cell Biology
The University of Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centenary Inst Of Cancer Medicine And Cell Biology, Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney filed Critical Centenary Inst Of Cancer Medicine And Cell Biology
Publication of AU2012357637A1 publication Critical patent/AU2012357637A1/en
Application granted granted Critical
Publication of AU2012357637B2 publication Critical patent/AU2012357637B2/en
Publication of AU2012357637B9 publication Critical patent/AU2012357637B9/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07004—Sulfate adenylyltransferase (2.7.7.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012357637A 2011-12-22 2012-12-20 Prevention and treatment of Mycobacterium infection Ceased AU2012357637B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161579166P 2011-12-22 2011-12-22
US61/579,166 2011-12-22
PCT/AU2012/001569 WO2013091004A1 (en) 2011-12-22 2012-12-20 Prevention and treatment of mycobacterium infection

Publications (3)

Publication Number Publication Date
AU2012357637A1 AU2012357637A1 (en) 2014-07-17
AU2012357637B2 AU2012357637B2 (en) 2017-09-21
AU2012357637B9 true AU2012357637B9 (en) 2017-10-19

Family

ID=48667508

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012357637A Ceased AU2012357637B9 (en) 2011-12-22 2012-12-20 Prevention and treatment of Mycobacterium infection

Country Status (7)

Country Link
US (2) US9610337B2 (enExample)
EP (1) EP2794885B1 (enExample)
CN (1) CN104271744B (enExample)
AU (1) AU2012357637B9 (enExample)
ES (1) ES2655190T3 (enExample)
IN (1) IN2014DN05865A (enExample)
WO (1) WO2013091004A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105567660B (zh) * 2016-01-08 2018-11-20 中国人民解放军第四军医大学 一种大肠杆菌重组表达结核分枝杆菌Rv2837c活性蛋白的方法及其应用
EP3743103A4 (en) * 2018-01-26 2021-03-17 The Regents of The University of California INTRANASAL ADMINISTRATION OF CYCLIC DI-NUCLEOTIDE ADJUVED VACCINE FOR TUBERCULOSIS
CA3098015A1 (en) * 2018-04-26 2019-10-31 Children's National Medical Center Mycobacterial antigen compositions and methods of use
EP3797791A1 (en) * 2019-09-26 2021-03-31 Universidad De Zaragoza Therapeutic efficacy by pulmonary delivery of live attenuated mycobacteria
WO2021243417A1 (en) * 2020-06-05 2021-12-09 Centenary Institute Of Cancer Medicine And Cell Biology Immunogenic formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ309945A (en) * 1995-05-23 2001-04-27 Univ California Abundant extracellular products and their use as vaccines
WO2002004018A2 (en) * 2000-07-10 2002-01-17 Colorado State University Research Foundation Mid-life vaccine and methods for boosting anti-mycobacterial immunity
WO2002086067A2 (en) 2001-04-20 2002-10-31 The Regents Of The University Of California Mycobacterial sulfation pathway proteins and methods of use thereof
US7074559B2 (en) * 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
EP2355798A1 (en) * 2008-11-12 2011-08-17 Statens Serum Institut Modified cationic liposome adjuvans

Also Published As

Publication number Publication date
CN104271744A (zh) 2015-01-07
US9931391B2 (en) 2018-04-03
US9610337B2 (en) 2017-04-04
IN2014DN05865A (enExample) 2015-05-22
ES2655190T3 (es) 2018-02-19
EP2794885B1 (en) 2017-10-04
EP2794885A1 (en) 2014-10-29
CN104271744B (zh) 2017-06-06
US20170173137A1 (en) 2017-06-22
EP2794885A4 (en) 2015-07-22
US20160022795A1 (en) 2016-01-28
WO2013091004A1 (en) 2013-06-27
AU2012357637B2 (en) 2017-09-21
AU2012357637A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
US8124068B2 (en) Recombinant intracellular pathogen immunogenic compositions and methods of use
EP2421557B1 (en) A tuberculosis tb vaccine to prevent reactivation
Singh et al. A century of BCG vaccination: Immune mechanisms, animal models, non-traditional routes and implications for COVID-19
JP5713523B2 (ja) エンドソームエスケープ能力増強組み換えｂｃｇ株類
US9931391B2 (en) Prevention and treatment of mycobacterium infection
US10010595B2 (en) Live recombinant booster vaccine against tuberculosis
Kwon et al. BCG-booster vaccination with HSP90-ESAT-6-HspX-RipA multivalent subunit vaccine confers durable protection against hypervirulent Mtb in mice
Prendergast et al. The Ag85B protein of the BCG vaccine facilitates macrophage uptake but is dispensable for protection against aerosol Mycobacterium tuberculosis infection
CN102439134B (zh) 包含过表达PhoP和/或PhoP调节子蛋白的重组BCG菌株的结核疫苗
LIN et al. Recombinant BCG coexpressing Ag85B, CFP10, and interleukin‐12 induces multifunctional Th1 and memory T cells in mice
Brun et al. Intranasal delivery of DNA encoding antigens of Mycobacterium tuberculosis by non-pathogenic invasive Escherichia coli
Wang et al. An attenuated Salmonella-vectored vaccine elicits protective immunity against Mycobacterium tuberculosis
Kondratieva et al. Mycobacterium tuberculosis attenuated by multiple deletions of rpf genes effectively protects mice against TB infection
Shanahan et al. Cutinase-like protein-6 of Mycobacterium tuberculosis is recognised in tuberculosis patients and protects mice against pulmonary infection as a single and fusion protein vaccine
Kong et al. Targeted induction of antigen expression within dendritic cells modulates antigen-specific immunity afforded by recombinant BCG
Romano et al. A Structural View at Vaccine Development Against M. tuberculosis. Cells 2023, 12, 317
Yin et al. Attenuated Listeria monocytogenes, a Mycobacterium tuberculosis ESAT-6 antigen expression and delivery vector for inducing an immune response
Torracinta et al. New Vaccine Strategies to Improve, Boost, or Replace BCG
Abil A novel mucosal vaccine formulation against tuberculosis by exploiting the adjuvant activity of S100A4—a damage-associated molecular pattern molecule
JP2022550722A (ja) 弱毒生マイコバクテリアの肺送達による治療有効性
Roche Role of T cell response during vaccine immunity to tuberculosis
Brodin et al. High Frequency of CD4
Kamanová Bordetella Adenylate Cyclase: Molecular Mechanism of Action and Its Use for Antigen Delivery
WO2016061115A1 (en) Bacterial vaccines deficient in the 2-c-methyl-d-erythritol-4-phosphate pathway and methods of preparation and use thereof

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired